Evidence map›Paper›PMID 31457035›Full record

ArticleIranian journal of biotechnology2018

Inhibitory Effect of Bismuth Oxide Nanoparticles Produced by

Leila Firouzi Dalvand, Farzaneh Hosseini, Shahram Moradi Dehaghi, Elham Siasi Torbati

Open access · diamondAbstract read
In one paragraph

Article in Iranian journal of biotechnology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.5field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 47 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Fabrication of pure BiScientific reports · 2024
    Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Microflow synthesis and enhanced photocatalytic dye degradation performance of antibacterial BiEnvironmental science and pollution research international · 2021
    Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Leila Firouzi DalvandDepartment of Microbiology, North Tehran Branch, Islamic Azad University, Tehran, Iran.
Farzaneh HosseiniDepartment of Microbiology, North Tehran Branch, Islamic Azad University, Tehran, Iran.
Shahram Moradi DehaghiDepartment of Chemistry, North Tehran Branch, Islamic Azad University, Tehran, Iran.
Elham Siasi TorbatiDepartment of Microbiology, North Tehran Branch, Islamic Azad University, Tehran, Iran.
Islamic Azad University North Tehran Branch · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundBased on the increase in antibiotic-resistant pathogens, it is necessary to have various effective compounds, so as to prevent its proliferation of these pathogens. For this purpose, nano-materials such as bismuth oxide nanoparticles can be used.

objectivesThe aim of this study was to produce bismuth oxide nanoparticles by MATERIALS AND

methodsIn this study, 200 bacterial samples were collected from hospitalized patients with burn infections from the Burn Rescue Hospital, Tehran. Thereafter, 65 strains of methicillin-resistant

resultsIn the present study, cube-shaped bismuth oxide nanoparticles were formed in the size range of 29-62 nm. They were found to have antimicrobial activity on 16% of the isolated

conclusionCompared with heavy metals, bismuth nanoparticles have very low antibacterial effects. Considering this feature, the use of less antibiotics can be achieved with bismuth nanoparticles in the treatment of infections, thereby reducing antibiotic resistance.

Indexed as

Bacillus licheniformisMethicillin-Resistance Staphylococcus aureusNanoparticles

Identifiers

PMID31457035
PMCPMC6697830
OpenAlexW2908267170

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.